The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients
Hyperphosphatemia
About this trial
This is an interventional treatment trial for Hyperphosphatemia focused on measuring Hyperphosphatemia, End Stage Renal Disease, Renal Osteodystrophy
Eligibility Criteria
Inclusion Criteria: Age > 18 years Capable of giving informed consent Duration of chronic hemodialysis > 90 days Dose of phosphorus binder(s) stable over previous 2 week period Serum Phosphorus > 4.9 mg/dL based on most recent laboratory data within 1 month of enrollment Exclusion Criteria: Pregnancy Known liver disease Active peptic ulcer disease Treatment with carbamazepine Intolerance to niacinamide Current medication regimen including niacin or niacinamide-containing vitamins More than 1 missed hemodialysis session in the last 30 days Planned or expected surgical procedure in the next 4 months Patients in nursing homes or extended care facilities where administration of the study drug may not be appropriately given
Sites / Locations
- Washington University Medical Center